CANDEL THERAPEUTICS, INC. (CADL) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -71.99M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 49.13M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-71.99M | (m) | (m) | $49.13M | (m) | (m) |
| 2026-03-31 | $-56.42M | (m) | (m) | $36.32M | (m) | (m) |
| 2025-12-31 | $-48.27M | (m) | (m) | $30.50M | (m) | (m) |
| 2025-09-30 | $-40.66M | (m) | (m) | $24.29M | (m) | (m) |
| 2025-06-30 | $-36.20M | (m) | (m) | $21.24M | (m) | (m) |
| 2025-03-31 | $-33.60M | (m) | (m) | $19.23M | (m) | (m) |
| 2024-12-31 | $-33.37M | (m) | (m) | $19.31M | (m) | (m) |
| 2024-09-30 | $-35.55M | (m) | (m) | $21.75M | (m) | (m) |
| 2024-06-30 | $-35.65M | (m) | (m) | $22.18M | (m) | (m) |
| 2024-03-31 | $-36.66M | (m) | (m) | $23.14M | (m) | (m) |
| 2023-12-31 | $-38.39M | (m) | (m) | $24.51M | (m) | (m) |
| 2023-09-30 | $-36.17M | (m) | (m) | $22.22M | (m) | (m) |
| 2023-06-30 | $-36.20M | (m) | (m) | $21.75M | (m) | (m) |
| 2023-03-31 | $-35.37M | (m) | (m) | $20.84M | (m) | (m) |
| 2022-12-31 | $-34.72M | $125.00K | (m) | $20.79M | (m) | -27777.60% |
| 2022-09-30 | $-34.36M | $125.00K | (m) | $19.67M | (m) | -27488.80% |
| 2022-06-30 | $-33.51M | $125.00K | (m) | $19.57M | (m) | -26806.40% |
| 2022-03-31 | $-30.05M | $125.00K | (m) | $17.84M | (m) | -24044.00% |
| 2021-12-31 | $-25.73M | $125.00K | (m) | $15.18M | (m) | -20580.80% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-13.81M | $125.00K | (m) | $8.75M | (m) | -11048.00% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |